PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2019-06, Vol.37 (S2), p.296-298
Hauptverfasser:	Zinzani, P.L., Armand, P., Ribrag, V., Michot, J., Kuruvilla, J., Zhu, Y., Farooqui, M., Nahar, A., Moskowitz, C.H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Hodgkin's lymphoma Immunotherapy Lymphoma Monoclonal antibodies Pembrolizumab Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	298
container_issue	S2
container_start_page	296
container_title	Hematological oncology
container_volume	37
creator	Zinzani, P.L. Armand, P. Ribrag, V. Michot, J. Kuruvilla, J. Zhu, Y. Farooqui, M. Nahar, A. Moskowitz, C.H.
description
doi_str_mv	10.1002/hon.106_2630
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2242712162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2242712162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c652-9410d8fa301821ff4deb78b9d81039b69b745177f237a35ae2f96cf7efd38e463</originalsourceid><addsrcrecordid>eNo1UEtOwzAUtBBIlMKOA1hiS8CfNB8WSG7rNFGdOkocSthEaRsLKmhLQhfsOAIX4HKcBJfC6s3TzJt5GgDOMbrCCJHrx_XKAKckDkUHoIOR71tm9w9BBxHXsxCh5BictO0SIcMhrwO-kpBlHOI-HPNiIhX__vhEmMJM5cMCygAmPO6nUkQPecz6MJrAhKmIT1QGp5EK4UCwLIsGMJTD0diwooiTUMYMskDxFPZTI83vo93tHR9KZSQBi0Se8huY8iwXxsik3Nqw4Cz9xYEUQk7NH3lyCo509dzWZ3-zC1TA1SC0hBxFAyasudMjlm9jtPB0RRH2CNbaXtQz15v5Cw8j6s8cf-baPey6mlC3or2qJtp35tqt9YJ6te3QLrjY226a9eu2bt_K5XrbrExiSYhNXEywQ4zqcq-aN-u2bWpdbpqnl6p5LzEqd_2Xpv_yv3_6A7jfbcg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242712162</pqid></control><display><type>article</type><title>PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zinzani, P.L. ; Armand, P. ; Ribrag, V. ; Michot, J. ; Kuruvilla, J. ; Zhu, Y. ; Farooqui, M. ; Nahar, A. ; Moskowitz, C.H.</creator><creatorcontrib>Zinzani, P.L. ; Armand, P. ; Ribrag, V. ; Michot, J. ; Kuruvilla, J. ; Zhu, Y. ; Farooqui, M. ; Nahar, A. ; Moskowitz, C.H.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.106_2630</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Hodgkin's lymphoma ; Immunotherapy ; Lymphoma ; Monoclonal antibodies ; Pembrolizumab ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2019-06, Vol.37 (S2), p.296-298</ispartof><rights>2019 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Zinzani, P.L.</creatorcontrib><creatorcontrib>Armand, P.</creatorcontrib><creatorcontrib>Ribrag, V.</creatorcontrib><creatorcontrib>Michot, J.</creatorcontrib><creatorcontrib>Kuruvilla, J.</creatorcontrib><creatorcontrib>Zhu, Y.</creatorcontrib><creatorcontrib>Farooqui, M.</creatorcontrib><creatorcontrib>Nahar, A.</creatorcontrib><creatorcontrib>Moskowitz, C.H.</creatorcontrib><title>PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP</title><title>Hematological oncology</title><subject>Hodgkin's lymphoma</subject><subject>Immunotherapy</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Pembrolizumab</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo1UEtOwzAUtBBIlMKOA1hiS8CfNB8WSG7rNFGdOkocSthEaRsLKmhLQhfsOAIX4HKcBJfC6s3TzJt5GgDOMbrCCJHrx_XKAKckDkUHoIOR71tm9w9BBxHXsxCh5BictO0SIcMhrwO-kpBlHOI-HPNiIhX__vhEmMJM5cMCygAmPO6nUkQPecz6MJrAhKmIT1QGp5EK4UCwLIsGMJTD0diwooiTUMYMskDxFPZTI83vo93tHR9KZSQBi0Se8huY8iwXxsik3Nqw4Cz9xYEUQk7NH3lyCo509dzWZ3-zC1TA1SC0hBxFAyasudMjlm9jtPB0RRH2CNbaXtQz15v5Cw8j6s8cf-baPey6mlC3or2qJtp35tqt9YJ6te3QLrjY226a9eu2bt_K5XrbrExiSYhNXEywQ4zqcq-aN-u2bWpdbpqnl6p5LzEqd_2Xpv_yv3_6A7jfbcg</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Zinzani, P.L.</creator><creator>Armand, P.</creator><creator>Ribrag, V.</creator><creator>Michot, J.</creator><creator>Kuruvilla, J.</creator><creator>Zhu, Y.</creator><creator>Farooqui, M.</creator><creator>Nahar, A.</creator><creator>Moskowitz, C.H.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201906</creationdate><title>PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP</title><author>Zinzani, P.L. ; Armand, P. ; Ribrag, V. ; Michot, J. ; Kuruvilla, J. ; Zhu, Y. ; Farooqui, M. ; Nahar, A. ; Moskowitz, C.H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c652-9410d8fa301821ff4deb78b9d81039b69b745177f237a35ae2f96cf7efd38e463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Hodgkin's lymphoma</topic><topic>Immunotherapy</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Pembrolizumab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zinzani, P.L.</creatorcontrib><creatorcontrib>Armand, P.</creatorcontrib><creatorcontrib>Ribrag, V.</creatorcontrib><creatorcontrib>Michot, J.</creatorcontrib><creatorcontrib>Kuruvilla, J.</creatorcontrib><creatorcontrib>Zhu, Y.</creatorcontrib><creatorcontrib>Farooqui, M.</creatorcontrib><creatorcontrib>Nahar, A.</creatorcontrib><creatorcontrib>Moskowitz, C.H.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zinzani, P.L.</au><au>Armand, P.</au><au>Ribrag, V.</au><au>Michot, J.</au><au>Kuruvilla, J.</au><au>Zhu, Y.</au><au>Farooqui, M.</au><au>Nahar, A.</au><au>Moskowitz, C.H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP</atitle><jtitle>Hematological oncology</jtitle><date>2019-06</date><risdate>2019</risdate><volume>37</volume><issue>S2</issue><spage>296</spage><epage>298</epage><pages>296-298</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.106_2630</doi><tpages>3</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0278-0232
ispartof	Hematological oncology, 2019-06, Vol.37 (S2), p.296-298
issn	0278-0232 1099-1069
language	eng
recordid	cdi_proquest_journals_2242712162
source	Wiley Online Library Journals Frontfile Complete
subjects	Hodgkin's lymphoma Immunotherapy Lymphoma Monoclonal antibodies Pembrolizumab Targeted cancer therapy
title	PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T20%3A14%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PHASE%201B%20KEYNOTE%E2%80%90013%20STUDY%20OF%20PEMBROLIZUMAB%20IN%20PATIENTS%20WITH%20CLASSIC%20HODGKIN%20LYMPHOMA%20AFTER%20BRENTUXIMAB%20VEDOTIN%20FAILURE:%20RESULTS%20OF%20%3E4%20YEARS%20OF%20FOLLOW%E2%80%90UP&rft.jtitle=Hematological%20oncology&rft.au=Zinzani,%20P.L.&rft.date=2019-06&rft.volume=37&rft.issue=S2&rft.spage=296&rft.epage=298&rft.pages=296-298&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.106_2630&rft_dat=%3Cproquest_cross%3E2242712162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242712162&rft_id=info:pmid/&rfr_iscdi=true